May 1, 1993Radiology

Contrast-enhanced transcranial Doppler US with a new transpulmonary echo contrast agent based on saccharide microparticles.

Q: What is the clinical evidence from this study?

Study design: Other. Population: Low or absent Doppler signals from the middle cerebral artery (n=20). Intervention: Transpulmonary galactose microparticle suspension (SH U 508 A) vs. Conventional Doppler US (baseline). Primary outcome: Doppler waveform analysis feasibility in middle cerebral arteries.

View Full Paper

Ask AI

Bookmark

Key result

Intravenous injection of a transpulmonary galactose microparticle suspension enabled Doppler waveform analysis in 93% of middle cerebral arteries with previously nondiagnostic signals.

Why the study?

Does a transpulmonary galactose microparticle contrast agent improve Doppler signal intensity in patients with nondiagnostic transcranial Doppler US?

Population

20 patients undergoing conventional transcranial Doppler US who had low or absent Doppler signals from the…

Comparison

Intravenous injection of a transpulmonary… vs Baseline

Design

Case_series

Follow-up

Immediate (during procedure)

Authors

KRK. A. RosenkranzPhilipps University of Marburg WZW. ZendelFreie Universität Berlin RLRuth LangerBoston College

Discussion

Member takes

Implication

May facilitate TCD in select cases; hypothesis-generating and should not yet change practice.

Structured PICO

Does a transpulmonary galactose microparticle contrast agent improve Doppler signal intensity in patients with nondiagnostic transcranial Doppler US?

Population

20 patients with low or absent Doppler signals from the middle cerebral artery undergoing conventional transcranial Doppler US.

Intervention

Intravenous injection of a transpulmonary galactose microparticle suspension (SH U 508 A) at three concentrations (200, 300, and 400 mg/mL).

Comparator

Baseline (conventional transcranial Doppler US without contrast)

Outcome

Extent and duration of Doppler signal increase in middle cerebral arteries and basilar arteriessurrogate

A new transpulmonary galactose microparticle contrast agent markedly increases Doppler signal intensity, enabling diagnostic waveform analysis in patients with previously nondiagnostic transcranial Doppler US.

Cite This Study

Rosenkranz et al. (1993) studied Low or absent Doppler signals from the middle cerebral artery (n=20). Transpulmonary galactose microparticle suspension (SH U 508 A) vs. Conventional Doppler US (baseline) was evaluated on Doppler waveform analysis feasibility in middle cerebral arteries. Intravenous injection of a transpulmonary galactose microparticle suspension enabled Doppler waveform analysis in 93% of middle cerebral arteries with previously nondiagnostic signals.

synapsesocial.com/papers/6a945b7b5cc4cfd2f72dd643 https://doi.org/10.1148/radiology.187.2.8475287

View Full Paper

Ask AI

Bookmark

Contrast-enhanced transcranial Doppler US with a new transpulmonary echo contrast agent based on saccharide microparticles.

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Contrast-enhanced transcranial Doppler US with a new transpulmonary echo contrast agent based on saccharide microparticles.

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider